(Q37696955)

22 August 2017

1 reference

title

IL-1 pathways in inflammation and human diseases (English)

1 reference

22 August 2017

0 references

1

Cem Gabay

1 reference

22 August 2017

Céline Lamacchia

2

1 reference

22 August 2017

Gaby Palmer

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

23 February 2010

1 reference

Nature Reviews Rheumatology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

232-241

1 reference

IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1beta processing and release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

21 January 2018

Pathogenesis of fever

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Nucleotide sequence of human monocyte interleukin 1 precursor cDNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Human interleukin-1 beta gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Crystallographic refinement of interleukin 1 beta at 2.0 A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Structure of interleukin 1 alpha at 2.7-A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Inflammasomes: guardians of cytosolic sanctity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The inflammasomes: guardians of the body

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

IL-1, IL-18, and IL-33 families of cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Active caspase-1 is a regulator of unconventional protein secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-33 is biologically active independently of caspase-1 cleavage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The interleukin-1 receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Critical regulation of early Th17 cell differentiation by interleukin-1 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Mutations in the IL1RN locus lead to autoinflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The two interleukin-1 receptors play different roles in IL-1 actions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

A central nervous system-restricted isoform of the interleukin-1 receptor accessory protein modulates neuronal responses to interleukin-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

IRAK-M is a negative regulator of Toll-like receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

At the horizon of innovative therapy in rheumatology: new biologic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Use of canakinumab in the cryopyrin-associated periodic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

An autoinflammatory disease due to homozygous deletion of the IL1RN locus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Anakinra for flares of pyogenic arthritis in PAPA syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

A role for geranylgeranylation in interleukin-1beta secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

A case of macrophage activation syndrome successfully treated with anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Gout-associated uric acid crystals activate the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

A pilot study of IL-1 inhibition by anakinra in acute gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Mice transgenic for intracellular interleukin-1 receptor antagonist type 1 are protected from collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Cytokine traps: multi-component, high-affinity blockers of cytokine action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.4

The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis

31 March 2020

1 reference

12 December 2020

The interleukin-1 family: 10 years of discovery

1 reference

12 December 2020

Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective.

1 reference

12 December 2020

Biologic basis for interleukin-1 in disease

1 reference

12 December 2020

Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates

1 reference

12 December 2020

Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor

1 reference

12 December 2020

Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis

1 reference

12 December 2020

The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense

1 reference

12 December 2020

The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor

1 reference

12 December 2020

Interleukin-1 receptor antagonist inhibits proteoglycan breakdown in antigen induced but not polycation induced arthritis in the rabbit

1 reference

12 December 2020

Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy.

1 reference

12 December 2020

Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2

1 reference

12 December 2020

Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor.

1 reference

12 December 2020

Major role for interleukin 1 but not for tumor necrosis factor in early cartilage damage in immune complex arthritis in mice

1 reference

12 December 2020

Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2010.4

1 reference

22 August 2017

1 reference